Related Experiment Video
Updated: Sep 10, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Dual-Targeting Mn@CeO2 Nanozyme-Modified Probiotic Hydrogel Microspheres Reshape Gut Homeostasis in Inflammatory
Pinwen Zhou1, Qi Sun2, Longchang Huang1
1Clinical Nutrition Service Center, Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.
Abstract:
Oral microecological agents show potential in reshaping intestinal microbiota and treating inflammatory bowel disease (IBD), but their clinical application is hindered by gastrointestinal challenges, antioxidant instability, and ineffective targeted delivery. In this study, we proposed a protective modification strategy utilizing a nanozyme coating and an alginate microsphere system to enhance the delivery efficiency, effectiveness, and precision of probiotics. By incorporating Mn into CeO2, Mn@CeO2 nanozyme was synthesized, significantly boosting ROS scavenging activity both in vitro and in vivo at safe dosages. Following the coincubation of Mn@CeO2 with Limosilactobacillus reuteri, the nanozymes were successfully distributed onto the surface of the probiotics. MnCe@LR/AMs were then fabricated using the electrostatic spray method, enhancing their tolerance to the acidic environment of the stomach. Notably, sodium alginate (SA), through electrostatic interactions and binding to mannose receptors highly expressed at inflamed sites, conferred a dual-targeting property to MnCe@LR/AMs. In the treatment of colitis in mice, MnCe@LR/AMs were shown to function through the synergistic antioxidant and anti-inflammatory activities of their components. They also effectively reinforced the intestinal barrier, while improving gut microbial diversity and increasing the relative abundance of probiotics. Furthermore, we demonstrated that MnCe@LR/AMs contribute to the maintenance of intestinal homeostasis by enhancing the absorption of amino acids in the gut and modulating macrophage polarization to regulate the immune response. These findings suggest that MnCe@LR/AMs hold significant promise for developing advanced IBD therapies, offering improved precision and efficacy in probiotic delivery.
Insights
This study developed nanozyme-coated probiotics encapsulated in alginate microspheres for improved inflammatory bowel disease (IBD) treatment. The novel delivery system enhances probiotic efficacy and targets inflamed gut regions, offering a promising therapeutic strategy.
Area of Science:
- Biomedical Engineering
- Microbiology
- Materials Science
Background:
- Oral probiotics show promise for inflammatory bowel disease (IBD) but face delivery challenges.
- Existing probiotics struggle with gastrointestinal survival, antioxidant stability, and targeted delivery to inflamed gut tissues.
Purpose of the Study:
- To develop an advanced probiotic delivery system for enhanced IBD treatment.
- To improve probiotic survival, targeted delivery, and therapeutic efficacy using nanozyme coating and alginate microspheres.
Main Methods:
- Synthesized Mn@CeO2 nanozymes to scavenge reactive oxygen species (ROS).
- Coated Limosilactobacillus reuteri with nanozymes and encapsulated them in sodium alginate microspheres (MnCe@LR/AMs) via electrostatic spray.
- Evaluated MnCe@LR/AMs in a mouse model of colitis.
Main Results:
- MnCe@LR/AMs demonstrated enhanced ROS scavenging and stability in acidic environments.
- The system exhibited dual-targeting to inflamed sites via mannose receptor binding.
- Treatment with MnCe@LR/AMs improved intestinal barrier function, microbial diversity, and probiotic abundance.
- Therapeutic effects included synergistic antioxidant/anti-inflammatory activities, enhanced amino acid absorption, and modulated macrophage polarization.
Conclusions:
- MnCe@LR/AMs represent a promising strategy for advanced IBD therapy.
- The nanozyme-alginate microsphere system significantly improves probiotic delivery precision and efficacy.
- This approach offers a novel platform for developing targeted microbiome-based therapies for IBD.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
06:38A Novel Method for the Culture and Polarized Stimulation of Human Intestinal Mucosa Explants
Published on: May 1, 2013
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Constipation-Predominant IBS